The European Commission had presented a report to the European Parliament and the Council, on progress made in children’s medicines since the Paediatric Regulation came into force 10 years ago. It concludes that positive advances in the development of medicines for children could not have been achieved without specific EU legislation – e.g. the authorisation of 260 new medicines. The Paediatric Regulation also gives a good return on investment. However, the report acknowledges that more effort is needed to combine the effects of the Paediatric with those of the Orphan medicines Regulation to address shortcomings in treating rare diseases in children.
Commenting on the report, VytenisAndriukaitis, Commissioner for Health and Food Safety, said: “Whereas I am pleased with the overall progress made in improving children’s access to safe, tailored medicines, I am committed to extending these positive gains to children with rare diseases. When we consider the advances in adult oncology, it upsets me deeply that we have not made the same progress in treating the cancers that affect children. In the next 10 years we must focus on making similar breakthroughs for children, by combining the incentives under the Orphans and the Paediatric Regulations, and by ensuring that the European Reference Networks – in particular ‘ERN PaedCan’ on paediatric cancer, reach full capacity”.
To read more about this on the European Commission website go to: http://europa.eu/rapid/press-release_IP-17-4121_en.htm